Systemic inflammation and functional capacity in elderly heart failure patients

Area of Science:

• Cardiology
• Biomarkers
• Heart Failure Research

Background:

• Elevated C-reactive protein (CRP) is linked to poor outcomes in heart failure (HF).
• Beta-blocker medications are known to potentially reduce CRP levels.

Purpose of the Study:

• To investigate the correlation between changes in high-sensitivity C-reactive protein (hs-CRP) levels and functional capacity in HF patients undergoing beta-blocker titration.
• To explore the relationship between hs-CRP, NT-proBNP, and the 6-minute walk test (6MWT) over a 12-week period.

Main Methods:

• 488 HF patients were enrolled, with measurements of hs-CRP, NT-proBNP, and 6MWT at baseline and 12 weeks.
• Patients were categorized into four groups based on hs-CRP level changes (low-low, high-high, low-high, high-low).
• Statistical analyses were performed to compare changes in NT-proBNP and 6MWT across the hs-CRP groups.

Main Results:

• Significant differences in NT-proBNP changes were observed between the hs-CRP groups (P=0.011).
• The 6-minute walk test (6MWT) changes also varied significantly across groups (P=0.002), with a decrease in the low-high hs-CRP group and improvement in the low-low group.
• NT-proBNP increased in the low-high group and decreased in the high-low group, while 6MWT showed opposing trends.

Conclusions:

• Post-beta-blocker treatment, hs-CRP levels demonstrate an association with functional capacity in heart failure patients.
• The findings suggest that hs-CRP levels may be a relevant indicator of functional status changes in HF.
• Further research is warranted to determine if targeting hs-CRP could be a viable therapeutic strategy in HF management.